Opthea (NASDAQ:OPT – Get Free Report) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Opthea to post earnings of ($0.43) per share for the quarter.
Opthea Stock Performance
Opthea stock opened at $5.04 on Wednesday. The business has a fifty day moving average of $4.27 and a two-hundred day moving average of $3.85. Opthea has a twelve month low of $1.79 and a twelve month high of $6.30.
Analysts Set New Price Targets
A number of research firms have weighed in on OPT. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Opthea in a report on Wednesday, January 29th. Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a research report on Tuesday, December 17th.
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More
- Five stocks we like better than Opthea
- Trading Halts Explained
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Roth IRA Calculator: Calculate Your Potential Returns
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What is the S&P 500 and How It is Distinct from Other Indexes
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
